Efficacy of mRNA and Inactivated Whole Virus Vaccines Against COVID-19 in Patients with Chronic Respiratory Diseases
Wang Chun Kwok,1,* Sze Him Isaac Leung,2,* Terence Chi Chun Tam,1 James Chung Man Ho,1 David Chi-Leung Lam,1 Mary Sau Man Ip,1 Pak Leung Ho3 1Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong Special Administrative Region, People’s Republic of China;...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2023-01-01
|
| Series: | International Journal of COPD |
| Subjects: | |
| Online Access: | https://www.dovepress.com/efficacy-of-mrna-and-inactivated-whole-virus-vaccines-against-covid-19-peer-reviewed-fulltext-article-COPD |
| _version_ | 1828058365515792384 |
|---|---|
| author | Kwok WC Leung SHI Tam TCC Ho JCM Lam DCL Ip MSM Ho PL |
| author_facet | Kwok WC Leung SHI Tam TCC Ho JCM Lam DCL Ip MSM Ho PL |
| author_sort | Kwok WC |
| collection | DOAJ |
| description | Wang Chun Kwok,1,* Sze Him Isaac Leung,2,* Terence Chi Chun Tam,1 James Chung Man Ho,1 David Chi-Leung Lam,1 Mary Sau Man Ip,1 Pak Leung Ho3 1Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong Special Administrative Region, People’s Republic of China; 2Department of Statistics, The Chinese University of Hong Kong, Hong Kong Special Administrative Region, People’s Republic of China; 3Department of Microbiology and Carol Yu Centre for Infection, The University of Hong Kong, Queen Mary Hospital, Hong Kong Special Administrative Region, People’s Republic of China*These authors contributed equally to this workCorrespondence: Pak Leung Ho, Department of Microbiology, The University of Hong Kong, Queen Mary Hospital, 102 Pokfulam Road, Pok Fu Lam, Hong Kong Special Administrative Region, People’s Republic of China, Tel +852 2255 2584, Fax +852 2855 1241, Email plho@hku.hkBackground: While different COVID-19 vaccines have been developed, there has been lack of data on the efficacy comparison between mRNA and inactivated whole virus vaccine among patients with chronic respiratory diseases, including asthma, chronic obstructive pulmonary disease (COPD), and bronchiectasis.Methods: This was a retrospective case control study on the efficacy of BNT162b2 (mRNA vaccine) and CoronaVac (inactivated whole virus vaccine) against COVID-19 in patients with chronic respiratory diseases. A total of 327 patients were included, with 109 patients infected with COVID-19 matched with 218 patients without COVID-19. The co-primary outcomes were vaccine effectiveness against symptomatic COVID-19, COVID-19-related hospitalization and COVID-19-related respiratory failure. Vaccine effectiveness was calculated using the formula (1-adjusted odds ratio) x 100.Results: Patients who received at least 2 doses of CoronaVac had lower risk of being hospitalized for COVID-19 and developing respiratory failure than those who did not have vaccination, with adjusted odds ratio (OR) of 0.189 (95% CI = 0.050– 0.714, p = 0.014) and 0.128 (95% CI = 0.026– 0.638, p = 0.012) respectively. Patients who received at least 2 doses of BNT162b2 had lower risk of being hospitalized for COVID-19 and developing respiratory failure than those who did not have vaccination with adjusted OR of 0.207 (95% CI = 0.043– 0.962, p = 0.050) and 0.093 (95% CI = 0.011– 0.827, p = 0.033) respectively. There was no statistically significant difference in the risks of being hospitalized for COVID-19 and developing respiratory failure between patients who received at least 2 doses of CoronaVac or BNT162b2.Conclusion: BNT162b2 and CoronaVac vaccines are effective in preventing hospitalization for COVID-19 and respiratory failure complicating COVID-19 among patients with chronic respiratory diseases. Patients with chronic respiratory diseases should be encouraged to have COVID-19 vaccination.Keywords: COVID-19, COPD, asthma, bronchiectasis, vaccine |
| first_indexed | 2024-04-10T21:26:04Z |
| format | Article |
| id | doaj.art-62e7405c58224bdaaa26f1449a4367dc |
| institution | Directory Open Access Journal |
| issn | 1178-2005 |
| language | English |
| last_indexed | 2024-04-10T21:26:04Z |
| publishDate | 2023-01-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | International Journal of COPD |
| spelling | doaj.art-62e7405c58224bdaaa26f1449a4367dc2023-01-19T17:31:54ZengDove Medical PressInternational Journal of COPD1178-20052023-01-01Volume 18475681081Efficacy of mRNA and Inactivated Whole Virus Vaccines Against COVID-19 in Patients with Chronic Respiratory DiseasesKwok WCLeung SHITam TCCHo JCMLam DCLIp MSMHo PLWang Chun Kwok,1,* Sze Him Isaac Leung,2,* Terence Chi Chun Tam,1 James Chung Man Ho,1 David Chi-Leung Lam,1 Mary Sau Man Ip,1 Pak Leung Ho3 1Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong Special Administrative Region, People’s Republic of China; 2Department of Statistics, The Chinese University of Hong Kong, Hong Kong Special Administrative Region, People’s Republic of China; 3Department of Microbiology and Carol Yu Centre for Infection, The University of Hong Kong, Queen Mary Hospital, Hong Kong Special Administrative Region, People’s Republic of China*These authors contributed equally to this workCorrespondence: Pak Leung Ho, Department of Microbiology, The University of Hong Kong, Queen Mary Hospital, 102 Pokfulam Road, Pok Fu Lam, Hong Kong Special Administrative Region, People’s Republic of China, Tel +852 2255 2584, Fax +852 2855 1241, Email plho@hku.hkBackground: While different COVID-19 vaccines have been developed, there has been lack of data on the efficacy comparison between mRNA and inactivated whole virus vaccine among patients with chronic respiratory diseases, including asthma, chronic obstructive pulmonary disease (COPD), and bronchiectasis.Methods: This was a retrospective case control study on the efficacy of BNT162b2 (mRNA vaccine) and CoronaVac (inactivated whole virus vaccine) against COVID-19 in patients with chronic respiratory diseases. A total of 327 patients were included, with 109 patients infected with COVID-19 matched with 218 patients without COVID-19. The co-primary outcomes were vaccine effectiveness against symptomatic COVID-19, COVID-19-related hospitalization and COVID-19-related respiratory failure. Vaccine effectiveness was calculated using the formula (1-adjusted odds ratio) x 100.Results: Patients who received at least 2 doses of CoronaVac had lower risk of being hospitalized for COVID-19 and developing respiratory failure than those who did not have vaccination, with adjusted odds ratio (OR) of 0.189 (95% CI = 0.050– 0.714, p = 0.014) and 0.128 (95% CI = 0.026– 0.638, p = 0.012) respectively. Patients who received at least 2 doses of BNT162b2 had lower risk of being hospitalized for COVID-19 and developing respiratory failure than those who did not have vaccination with adjusted OR of 0.207 (95% CI = 0.043– 0.962, p = 0.050) and 0.093 (95% CI = 0.011– 0.827, p = 0.033) respectively. There was no statistically significant difference in the risks of being hospitalized for COVID-19 and developing respiratory failure between patients who received at least 2 doses of CoronaVac or BNT162b2.Conclusion: BNT162b2 and CoronaVac vaccines are effective in preventing hospitalization for COVID-19 and respiratory failure complicating COVID-19 among patients with chronic respiratory diseases. Patients with chronic respiratory diseases should be encouraged to have COVID-19 vaccination.Keywords: COVID-19, COPD, asthma, bronchiectasis, vaccinehttps://www.dovepress.com/efficacy-of-mrna-and-inactivated-whole-virus-vaccines-against-covid-19-peer-reviewed-fulltext-article-COPDcovid-19copdasthmabronchiectasisvaccine |
| spellingShingle | Kwok WC Leung SHI Tam TCC Ho JCM Lam DCL Ip MSM Ho PL Efficacy of mRNA and Inactivated Whole Virus Vaccines Against COVID-19 in Patients with Chronic Respiratory Diseases International Journal of COPD covid-19 copd asthma bronchiectasis vaccine |
| title | Efficacy of mRNA and Inactivated Whole Virus Vaccines Against COVID-19 in Patients with Chronic Respiratory Diseases |
| title_full | Efficacy of mRNA and Inactivated Whole Virus Vaccines Against COVID-19 in Patients with Chronic Respiratory Diseases |
| title_fullStr | Efficacy of mRNA and Inactivated Whole Virus Vaccines Against COVID-19 in Patients with Chronic Respiratory Diseases |
| title_full_unstemmed | Efficacy of mRNA and Inactivated Whole Virus Vaccines Against COVID-19 in Patients with Chronic Respiratory Diseases |
| title_short | Efficacy of mRNA and Inactivated Whole Virus Vaccines Against COVID-19 in Patients with Chronic Respiratory Diseases |
| title_sort | efficacy of mrna and inactivated whole virus vaccines against covid 19 in patients with chronic respiratory diseases |
| topic | covid-19 copd asthma bronchiectasis vaccine |
| url | https://www.dovepress.com/efficacy-of-mrna-and-inactivated-whole-virus-vaccines-against-covid-19-peer-reviewed-fulltext-article-COPD |
| work_keys_str_mv | AT kwokwc efficacyofmrnaandinactivatedwholevirusvaccinesagainstcovid19inpatientswithchronicrespiratorydiseases AT leungshi efficacyofmrnaandinactivatedwholevirusvaccinesagainstcovid19inpatientswithchronicrespiratorydiseases AT tamtcc efficacyofmrnaandinactivatedwholevirusvaccinesagainstcovid19inpatientswithchronicrespiratorydiseases AT hojcm efficacyofmrnaandinactivatedwholevirusvaccinesagainstcovid19inpatientswithchronicrespiratorydiseases AT lamdcl efficacyofmrnaandinactivatedwholevirusvaccinesagainstcovid19inpatientswithchronicrespiratorydiseases AT ipmsm efficacyofmrnaandinactivatedwholevirusvaccinesagainstcovid19inpatientswithchronicrespiratorydiseases AT hopl efficacyofmrnaandinactivatedwholevirusvaccinesagainstcovid19inpatientswithchronicrespiratorydiseases |